{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-033196","form_type":"8-K","ticker":"ANEB","cik":"0001815974","company_name":"Anebulo Pharmaceuticals, Inc.","filed_at":"2023-09-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.387786+00:00","generated_at":"2026-06-10T12:20:44.289320+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Anebulo reports FY2023 net loss of $11.7M; cash $11.2M; FDA supports Phase 3","bullets":["Net loss for FY2023 was $11.7M ($0.47 per share) vs $6.8M ($0.29) in FY2022.","Cash and cash equivalents at June 30, 2023 were $11.2 million.","Positive FDA Type B meeting supports advancing ANEB-001 to registrational studies; Phase 3 targeting H1 2024.","Dosing completed in Part C open-label extension of Phase 2 study; data readout expected Q4 2023.","Operating expenses in FY2023 were $11.8M, up from $6.8M, driven by R&D and G&A increases."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-033196","json":"https://secwatch.observer/filing/0001493152-23-033196.json","markdown":"https://secwatch.observer/filing/0001493152-23-033196.md","text":"https://secwatch.observer/filing/0001493152-23-033196.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815974/000149315223033196/0001493152-23-033196-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815974/000149315223033196/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T12:20:44.289320+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"80566c5201a2a029f33b2f967a0d16ff91535f02","claim":"Anebulo Pharmaceuticals, Inc. reported three months ended June 30, 2023 results: net income Net loss in the fourth quarter of fiscal 2023 was $2.5 million, or $(0.10) per share, EPS $(0.10) per share.","evidence_excerpt":"Net loss in the fourth quarter of fiscal 2023 was $2.5 million, or $(0.10) per share, compared with a net loss of $2.3 million, or $(0.10) per share, in the fourth quarter of fiscal 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815974/000149315223033196/0001493152-23-033196-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended June 30, 2023"},{"label":"Net income","value":"Net loss in the fourth quarter of fiscal 2023 was $2.5 million, or $(0.10) per share"},{"label":"EPS","value":"$(0.10) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ec95133bed5190f58cc0dc64cb83fde538a6a4f9","claim":"Anebulo Pharmaceuticals, Inc. reported twelve months ended June 30, 2023 results: net income Net loss in fiscal year 2023 was $11.7 million, or $(0.47) per share, EPS $(0.47) per share.","evidence_excerpt":"Net loss in fiscal year 2023 was $11.7 million, or $(0.47) per share, compared with a net loss of $6.8 million, or $(0.29) per share, in fiscal year 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815974/000149315223033196/0001493152-23-033196-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"twelve months ended June 30, 2023"},{"label":"Net income","value":"Net loss in fiscal year 2023 was $11.7 million, or $(0.47) per share"},{"label":"EPS","value":"$(0.47) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}